<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16362711</article-id><article-id pub-id-type="pmc">3452063</article-id><article-id pub-id-type="publisher-id">233</article-id><article-id pub-id-type="doi">10.1007/s10194-005-0233-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Effect of preventive treatment on health&#x02013;related quality of life in episodic migraine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bordini</surname><given-names>C. A.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>H. Mariano</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Garbelini</surname><given-names>R. P.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Teixeira</surname><given-names>S. O.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Speciali</surname><given-names>J. G.</given-names></name><address><phone>+55-16-6022548</phone><fax>+55-16-6330866</fax><email>hiltonmariano@uol.com.br</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Neurology, S&#x000e3;o Paulo University,
School of Medicine at Ribeir&#x000e3;o Preto, Av. Bandeirantes 3900, 14049-900 Ribeir&#x000e3;o Preto, SP, Brazil </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>8</month><year>2005</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2005</year></pub-date><volume>6</volume><issue>5</issue><fpage>387</fpage><lpage>391</lpage><history><date date-type="received"><day>2</day><month>4</month><year>2005</year></date><date date-type="accepted"><day>31</day><month>5</month><year>2005</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag Italia 2005</copyright-statement></permissions><abstract id="Abs1"><p>The purpose of our study
was to prospectively evaluate the
impact of preventive drug treatment
on the quality of life of patients
with episodic migraine (EM).
Quality of life evaluations can
enhance traditional measures of
therapeutic efficacy. Thirty&#x02013;five
consecutive EM without aura
patients attending a tertiary care
unit (Batatais Headache Clinic)
entered the study. They were given
a prescription for preventive medication
and completed the validated
Portuguese version of the generic
instrument Short Form&#x02013;36 (SF&#x02013;36)
questionnaire. Six months later,
patients were given another SF&#x02013;36.
We compared the pre&#x02013;treatment and
post&#x02013;treatment scores for the SF&#x02013;36
and analysed the headache diaries.
The mean age of the 35 patients (32
women and 3 men) was 40.2 years
(range 18&#x02013;60 years). All 35 patients
completed the pretreatment and follow&#x02013;up SF&#x02013;36. The pre&#x02013;treatment
and post&#x02013;treatment mean frequency
of migraine attacks was 9.16 and
2.4 crises per month, respectively
(<italic>p</italic>&#x0003c;0.05). After the six months of
preventive treatment, six of the
eight domains evaluated by the SF&#x02013;36 (role physical, bodily pain, general
health, vitality, social function
and mental health) showed statistically
significant (<italic>p</italic>&#x0003c;0.05) improvement.
The preventive treatment of
migraine leads to a significant
improvement in the quality of life
of patients with EM. This improvement
was measurable by the general
quality of life instrument SF&#x02013;36.</p></abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>Headache</kwd><kwd>Migraine</kwd><kwd>Health&#x02013;related quality of life</kwd><kwd>Preventive treatment</kwd><kwd>SF&#x02013;36</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Italia 2005</meta-value></custom-meta></custom-meta-group></article-meta></front></article>
